Clinical Trial

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-17; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-10-08
Trial Details
NCT Number NCT07027514
Lead Sponsor Ankyra Therapeutics, Inc
Conditions Non Small Cell Lung Cancer
Enrollment 60 participants
Start Date 2025-10-22
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-18